<DOC>
	<DOCNO>NCT02460419</DOCNO>
	<brief_summary>This multicenter , randomise , phase 3 study evaluate survival benefit maintenance capecitabine plus best supportive care versus best supportive care metastatic nasopharyngeal carcinoma patient disease control TPC palliative chemotherapy .</brief_summary>
	<brief_title>Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care Metastatic Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Firstly diagnose metastatic nasopharyngeal carcinoma patient receive 4-6 cycle palliative chemotherapy taxol , cisplatin capecitabine . After disease control , randomly assign maintenance capecitabine plus best supportive care ( BSC ) BSC alone . The primary end point progression-free survival , secondary end point overall survival , duration response , objective response rate , adverse effect quality life .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Firstly diagnose metastatic nasopharyngeal carcinoma patient Disease control 46 cycle palliative chemotherapy taxol , cisplatin capecitabine Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectation least 12 week No systemic chemotherapy within 6 month , except induction chemotherapy concurrent chemotherapy With least one measurable lesion Enough blood test Signed informed consent Sever heart disease HIV infection Sever infection Brain metastasis , except receive radical therapy 6 month ago stable 4 week Allogeneic organ transplantation Malignancy nasopharyngeal carcinoma , except : cervical carcinoma situ , cure basal cell carcinoma , bladder cancer Ta , Tis T1 , cure cancer least 3 year Pregnancy breast feed Difficulty swallow Received test drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>metastasis</keyword>
	<keyword>capecitabine</keyword>
</DOC>